4//SEC Filing
DiRocco Derek 4
Accession 0001209191-22-036135
CIK 0001808865other
Filed
Jun 9, 8:00 PM ET
Accepted
Jun 10, 7:48 PM ET
Size
9.8 KB
Accession
0001209191-22-036135
Insider Transaction Report
Form 4
DiRocco Derek
Director
Transactions
- Award
Stock Option (Right to Buy)
2022-06-09+17,538→ 17,538 totalExercise: $18.78Exp: 2032-06-09→ Common Stock (17,538 underlying)
Footnotes (2)
- [F1]This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 9, 2023 or (b) the next annual meeting of the Issuer's stockholders.
- [F2]Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund") and the RA Capital Nexus Fund, L.P. (the "Nexus Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund and the Nexus Fund. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock.
Documents
Issuer
iTeos Therapeutics, Inc.
CIK 0001808865
Entity typeother
Related Parties
1- filerCIK 0001792061
Filing Metadata
- Form type
- 4
- Filed
- Jun 9, 8:00 PM ET
- Accepted
- Jun 10, 7:48 PM ET
- Size
- 9.8 KB